Professor Sam Salek, School of Medical and Life Sciences, University of Hertfordshire, calls for a “universal framework” to speed up the disjointed decision-making process around the commissioning of new drugs
Discussing the potential “doomsday scenario” of a world without antibiotics, Professor Colin Garner, chief executive of Antibiotic Research UK (ANTRUK), says “not all is…bleak” as efforts are being made to remedy the situation
Charlie Cunningham, Colorcon, says continuous coating by far outperforms traditional batch coating and is fast catching on with pharmaceutical customers.
Oliver Wright, solicitor at law firm LHS, says a new high court ruling means improved transparency and a clearer framework for companies operating under regulation by the Health Research Authority
Benjamin J Lehberger, St Onge Steward Johnston & Reens LLC, looks at patent challenges in the pharmaceutical industry and a recent trend of investment companies challenging the patents of foreign pharmaceutical manufacturers.
Mergers & acquisitions – it’s all about collaboration, says Mike Straw, Achieve Breakthrough. He argues that deals are all about people as well as the numbers – and it’s the collaboration that will make a deal truly work.
Dr. Julien Meissonnier, Pharmaceutical Softgel Europe, Catalent looks at lipid-based formulations to increase the bioavailability of poorly soluble drugs.
